Downregulation of IL-8, ECP, and total IgE in the tears of patients with atopic keratoconjunctivitis treated with rebamipide eyedrops.
Downregulation of IL-8, ECP, and total IgE in the tears of patients with atopic keratoconjunctivitis treated with rebamipide eyedrops.
复制标题
DOI：
10.1186/2045-7022-4-40
复制
发表时间：
2014
影响因子：
4.4
通讯作者：
Kinoshita S
中科院分区：
文献类型：
--
作者：
Ueta M;Shoji J;Sotozono C;Kinoshita S
利巴米胺滴眼液在日本被批准用于治疗干眼症。部分变应性结膜疾病患者还会出现干眼症。早期我们报道了利巴米胺抑制人结膜上皮细胞中多聚c诱导的炎症细胞因子。在本研究中，我们检测了利巴米胺滴眼液对眼表面白细胞介素-8 （IL-8）、嗜酸性阳离子蛋白（ECP）和总IgE水平的影响。我们给出现干眼症状的特应性角膜结膜炎（AKC）患者（4例AKC患者中有6只眼）开了利巴米胺滴眼液，并在开始利巴米胺治疗前、2周和4 - 6周后测量了他们泪液中的IL-8、ECP和总IgE水平。为了测量泪液中IL-8和总IgE水平，我们使用了BD™CBA Flex套装；ECP测定采用ELISA法。利巴米胺治疗4-6周后，AKC患者泪液中IL-8、ECP、总IgE水平显著降低。我们还通过患者问卷记录了与AKC相关的主观症状，如瘙痒、异物感和眼粘液排出。在2周和4-6周时，与AKC相关的主观症状也显著改善。我们的观察结果表明，利巴米胺滴眼液的抗炎作用有助于对抗人类眼表炎症，它们可能是AKC患者的一种新的有效治疗方法。本文的在线版本（doi:10.1186/2045-7022-4-40）包含补充材料，仅供授权用户使用。
Rebamipide eyedrops are approved in Japan for the treatment of dry eye disease. Some patients with allergic conjunctival diseases also manifest dry eye. Earlier we reported that rebamipide suppressed polyI:C-induced inflammatory cytokines in human conjunctival epithelial cells. In the current study we examined the effect of rebamipide eyedrops on the level of interleukin-8 (IL-8), eosinophil cationic protein (ECP), and total IgE on the ocular surface. We prescribed rebamipide eyedrops to patients with atopic keratoconjunctivitis (AKC) who presented with dry eye (6 eyes in 4 AKC patients) and measured the IL-8, ECP, and total IgE levels in their tears before- and 2, and 4–6 weeks after the start of rebamipide treatment. To measure the IL-8 and total IgE levels in their tears we used BD™ CBA Flex sets; ECP measurements were with ELISA. The level of IL-8, ECP, and total IgE in the tears of AKC patients was reduced significantly 4–6 weeks after the start of rebamipide treatment. We also recorded subjective symptoms associated with AKC, e.g. itching, foreign body sensation, and eye mucus discharge, by using a patient questionnaire. Their subjective symptoms associated with AKC were also significantly ameliorated at 2 and 4–6 weeks. Our observations suggest that the anti-inflammatory effects of rebamipide eyedrops help to combat human ocular surface inflammation and that they may be a new effective therapy in patients with AKC. The online version of this article (doi:10.1186/2045-7022-4-40) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
4.2
作者：
Kinoshita, Shigeru;Awamura, Saki;Yoko, Norihiko
通讯作者：
Yoko, Norihiko
影响因子：
6.8
作者：
Ueta, Mayumi;Sotozono, Chie;Kinoshita, Shigeru
通讯作者：
Kinoshita, Shigeru
影响因子：
13.7
作者：
Kinoshita, Shigeru;Awamura, Saki;Yokoi, Norihiko
通讯作者：
Yokoi, Norihiko
影响因子：
3.1
作者：
Murakami, K;Okajima, K;Takatsuki, K
通讯作者：
Takatsuki, K
影响因子：
2.4
作者：
Shoji, J;Kitazawa, M;Kato, H
通讯作者：
Kato, H